Diaceutics Launches New
Service and Signs First Contract for up to $1.8m
New Pathology Engagement
Liaisons service (PEL) launched
PEL will augment the suite
of services available under Diaceutics' PMx commercialisation
solution and increase the available revenue per brand for
Diaceutics
Belfast and London, 8 January 2025 - Diaceutics PLC
(AIM: DXRX), a leading technology and solutions
provider to the pharma and biotech industry, is pleased to announce
that it has launched its new Pathology Engagement Liaisons (PEL)
service and secured its first contract worth up to $1.8 million
over 12 months. The new contract is with an existing customer ("the
Customer"), a top twenty global pharma company, and
will facilitate the outreach and
education of laboratory pathologists
for pancreatic cancer testing
in the US market.
There are limited options currently
available that enable pharma companies to engage directly with
laboratories and pathologists at scale. The launch of PEL will
allow Diaceutics to utilise the DXRX platform and its laboratory
network to engage pathologists in biomarker testing and diagnostic
focused education, supporting best in class biomarker-test-adoption
and implementation within laboratories globally.
Susanne
Munksted, Chief Precision Medicine Officer at Diaceutics,
commented: "It is very exciting to continue to build our
product utilising the DXRX lab network in the US. More importantly,
this engagement will make a significant difference to patient lives
with us working closely with our pharma customer to bring this new
therapy option to patients in need".
This first contract win will see
Diaceutics roll out PEL across existing
DXRX network laboratories in the US to support the
outreach and engagement of
pathologists performing immunohistochemistry testing
for pancreatic cancer patients. This will
drive biomarker education, testing and awareness
related to the Customer's newly approved therapy
and ultimately, is expected, will improve patient identification
and clinical outcomes.
This first contract win for PEL is
as a standalone service. However, PEL can also be deployed under
Diaceutics' PMx commercialisation solution, helping to optimise
laboratory testing and patient recruitment to therapy. PEL further
enhances the relevance of Diaceutics' services to therapy brands
and increases the revenue per brand available to
Diaceutics.
Contract & Terms
This contract extends to the end of
2025 and will be worth up to $1.8 million in revenue over the term
of the contract.
Enquiries:
|
Diaceutics
PLC
|
|
|
Ryan Keeling, Chief Executive
Officer
Nick Roberts, Chief Financial
Officer
|
Tel: +44 (0)28 9040 6500
investorrelations@diaceutics.com
|
|
|
|
|
Canaccord
Genuity Limited (Nomad &
Broker)
|
Tel: +44 (0)20 7523 8000
|
|
Simon Bridges, Andrew Potts, Harry
Rees
|
|
About Diaceutics
At Diaceutics we
believe that every patient should get the opportunity to
receive the right test and the right therapy to positively impact
their disease outcome. We provide the world's leading pharma and
biotech companies with an end-to-end commercialisation solution for
precision medicines through data analytics, scientific and advisory
services enabled by our platform DXRX - The Diagnostics
Network®.
This announcement contains inside
information for the purposes of Article 7 of Regulation (EU)
596/2014 as it forms part of UK domestic law by virtue of the
European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in
accordance with the Company's obligations under Article 17 of
MAR.
The person responsible for making
this announcement on behalf of the Company is Nick Roberts, Chief
Financial Officer.
